Solid Biosciences files $200 million at-the-market share sale program with Jefferies
Solid Biosciences filed a prospectus supplement under its existing shelf registration to offer up to $200.0 million of common stock through a sales agreement with Jefferies LLC. The company said it had already sold about $85.0 million of stock under a prior supplement, which it will no longer use once this one is filed.
Key points
- Up to $200.0 million of common stock may be sold under the Amended and Restated Sales Agreement dated March 13, 2024 with Jefferies LLC.
- Prior prospectus supplement covered up to $85.0 million; about $85.0 million in gross proceeds had been raised under it and the Sales Agreement as of the filing date.
- Offering is made under the Form S-3 shelf registration (File No. 333-287325), declared effective May 27, 2025.
- Wilmer Cutler Pickering Hale and Dorr LLP issued a legal opinion on the shares (Exhibit 5.1).
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.